U.S. Markets close in 4 hrs 44 mins

Acura Pharmaceuticals, Inc. (ACUR)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.54+0.02 (+3.39%)
As of 10:42AM EDT. Market open.
People also watch
ABIOAPRIALIMAEZSCLSN
Full screen
Previous Close0.52
Open0.53
Bid0.00 x
Ask0.00 x
Day's Range0.53 - 0.54
52 Week Range0.40 - 2.09
Volume5,100
Avg. Volume12,915
Market Cap6.42M
Beta2.06
PE Ratio (TTM)-1.74
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
    Capital Cube2 months ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Acura Pharmaceuticals, Inc. – Windtree Therapeutics, Inc., Innoviva, Inc., Aradigm Corporation, Johnson & Johnson, OPKO Health, Inc., Pfizer Inc., Nektar Therapeutics, Rigel Pharmaceuticals, Inc. and Pain Therapeutics, Inc. ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Acura Pharmaceuticals, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Acura Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to ACUR-US. Comparing the performance and risk of Acura Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
    Capital Cube4 months ago

    Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017

    Categories: Yahoo FinanceGet free summary analysis Acura Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. Highlights Summary numbers: Revenues of USD 3.77 million, Net Earnings of USD 1.53 million. Gross margins widened from 96.19% to 96.23% compared to the same period last year, operating (EBITDA) margins now 48.21% from -23.33%. Change in operating ... Read more (Read more...)